Oculis Holding AG
Oculis Holding AG (OCS) Covered Calls
As of September 23, 2026, OCS has 6 covered call opportunities in the coming three months. Return ranges from 1.1 to 53.2% until expiration. Annualized return ranges from 2.7 to 130.2%. The nearest expiration is November 20, 2026. Maximum potential profit is $531.
Read more
Running OCS covered calls helps you generate consistent income from Oculis Holding AG's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Oculis Holding AG involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best OCS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if OCS stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling OCS covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Oculis Holding AG covered call is worth writing.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
The company is based in Zug, Switzerland.
Income-focused investors, long-term OCS holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling OCS covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Oculis Holding AG covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile—
- Market cap (M$)615
- 52 weeks high-71.03%
- 52 weeks low3.52%
- Analyst recommendationStrong Buy
1.09 - Target price$36.70
287.05% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-1.76
- EPS growth next 5 years9.57%
As of September 23, 2026
| 2027-02-19 | 149 | 15.00 | 50.15 | 0.30 | 4.90 | 531.00 | 53.15 | 130.21 | -3.00 | +0.54 | 38 | 4.60 |
| 2027-02-19 | 149 | 12.50 | 25.13 | 0.20 | 4.90 | 271.00 | 27.13 | 66.45 | -2.00 | +0.57 | 27 | 4.70 |
| 2026-11-20 | 58 | 10.00 | 0.10 | 1.00 | 2.40 | 101.00 | 10.11 | 63.62 | -10.01 | +0.59 | 407 | 1.40 |
| 2027-05-21 | 240 | 12.50 | 25.13 | 0.10 | 4.90 | 261.00 | 26.13 | 39.73 | -1.00 | +0.56 | 0 | 4.80 |
| 2027-05-21 | 240 | 10.00 | 0.10 | 0.30 | 4.90 | 31.00 | 3.10 | 4.72 | -3.00 | +0.64 | 0 | 4.60 |
| 2027-02-19 | 149 | 10.00 | 0.10 | 0.10 | 4.90 | 11.00 | 1.10 | 2.70 | -1.00 | +0.63 | 15 | 4.80 |
As of September 23, 2026
Sell covered calls with the data behind you
Find the best OCS covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→